DataSheet_1_Features of patients with advanced EGFR-mutated non-small cell lung cancer benefiting from immune checkpoint inhibitors.docx

BackgroundAlthough immune checkpoint inhibitors (ICIs) generally show poor therapeutic efficacy in patients with epidermal growth factor receptor (EGFR) mutations, certain research indicate that a small proportion of these patients do respond to ICIs. The present study sought to identify the features of patients with EGFR mutations who might benefit from ICIs from multiple studies and discussed the optimal treatment paradigm for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations.MethodsThe profiles of 114 advanced NSCLC patients with EGFR mutations who received ICIs treatment were retrospectively reviewed. EGFR subtypes, programmed cell death ligand 1 (PD-L1) expression, and clinical characteristics regarding their impact on the efficacy of ICIs were investigated.ResultsPatients with major EGFR mutations (L858R or 19Del) had a shorter progression-free survival (PFS) and a lower objective response rate (ORR) as compared to patients with rare (20ins or G719X) and other EGFR mutations. Although not statistically significant, median overall survival (OS) tended to be longer in patients with negative (ConclusionPatients with major EGFR mutations showed poorer responses to ICIs than those with rare EGFR mutations. EGFR-mutated patients with lower PD-L1 expression showed a trend towards a longer OS after receiving ICIs. ICIs should be administered as early as possible to previously treated EGFR-mutated NSCLC patients. ICI-based combined therapies may be a direction for treatment of these patient subtypes in the future.</p

Additional file 1 of Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

Supplementary Material 1: Survival curves of NTRK1/2/3 mutated NSCLC patients in the TMB-low grou

Additional file 1: Figure S1. of MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression

Confirmation of miR-381 overexpression in gastric cancer cells. QRT-PCR analysis of miR-381 transfection efficiency after agomiR-381 and negative control transfection in AGS and BGC-823 cell lines. (TIF 31 kb

Additional file 2: Figure S2. of MicroRNA-381 inhibits the metastasis of gastric cancer by targeting TMEM16A expression

Confirmation of miR-381 low-expression in gastric cancer cells. QRT-PCR analysis of miR-381 transfection efficiency after antagomiR-381 and negative control transfection in MKN-28 and SGC-7901 cell lines. (TIF 29 kb

Additional file 1 of Mesoporous silica nanoparticle-encapsulated Bifidobacterium attenuates brain Aβ burden and improves olfactory dysfunction of APP/PS1 mice by nasal delivery

Additional file 1: Figure S1. Characterization of MSNs. a Transmission electron micrographs of MSNs of different sizes (scale bar = 200 nm). b Corresponding histogram and Gaussian fit of the measured MSN size distribution. Figure S2. Absorption spectroscopy of MSN-Cy3, FITC-Bifidobacterium, and MSNs-Bifidobacterium. Figure S3. Representative images of colonies formed by MSNs-Bi on the culture medium were used to evaluate the activity of Bifidobacterium in Krebs-Henseleit solution. Figure S4. Characterization of MSN-encapsulated Bifidobacterium and E. coli. MSNs loading rates for Bifidobacterium (a) and E. coli (b) and the viability of Bifidobacterium (c) and E. coli (d) during exposure to SIF. Figure S5. Distribution of MSNs-Bi in the gastrointestinal tract after intranasal administration. DAPI (blue), FITC (green), and Cy3 (Red). (scale bar = 200 μm). Figure S6. Distribution of MSNs-Bi in the lung after intranasal administration. DAPI (blue), FITC (green), and Cy3 (Red). (scale bar = 200 μm). Figure S7. Alpha diversity analysis of the gut microbiome of C57BL/6 mice (WT) and APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi. Bi refers to Bifidobacterium. Boxplots show the index of Chao1, ACE, and Shannon. Figure S8. The area fraction of ThioS-stained Aβ plaques in the stomach, duodenum, jejunum, ileum, cecum, and colon from APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi. Two-way ANOVA, ****P < 0.001. Figure S9. IP-Western blotting images of the brain, spinal cord, blood, stomach, duodenum, jejunum, ileum, cecum, and colon from APP/PS1 mice treated with PBS, MSNs, Bifidobacterium, and MSNs-Bi. Figure S10. Relative fluorescence intensity was used to monitor changes in the level of Cy3 in MSNs

Crystallographic data in CIF from Investigation on the hydrolytic mechanism of cucurbit[6]uril in alkaline solution

Single Crystal Structure in CIF of 3 hydrolysis products

DataSheet_1_CDC25C as a Predictive Biomarker for Immune Checkpoint Inhibitors in Patients With Lung Adenocarcinoma.zip

The application of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer has significantly improved patient survival. However, most patients fail to respond to ICIs or develop drug resistance during treatment. Therefore, novel biomarkers are needed to predict the efficacy of ICIs or provide clues on how to overcome drug resistance. Here, it was revealed that cell division cycle 25C (CDC25C) expression was upregulated in lung adenocarcinoma (LUAD) compared to that of normal lung tissue in multiple databases. This was further verified by q-PCR. Furthermore, higher CDC25C expression was associated with shorter overall survival and worse pathological stage. Most importantly, a higher CDC25C expression was associated with shorter progression-free survival in LUAD patients treated with nivolumab, suggesting the role of the cell cycle in immunotherapy. In addition, CDC25C expression was significantly associated with immune cell infiltration and immune-related signatures in the LUAD tumor microenvironment. Moreover, CDC25C was differentially expressed and correlated with overall survival in multiple tumors, indicating that CDC25C is a broad-spectrum biomarker. Taken together, our study demonstrates that CDC25C is a prognostic biomarker for LUAD patients, especially for patients treated with ICIs. Our study also provides strong evidence for the role of the cell cycle in ICIs therapy and tumor microenvironment.</p

Crystallographic data in CIF from Investigation on the hydrolytic mechanism of cucurbit[6]uril in alkaline solution

Single Crystal Structure in CIF of 3 hydrolysis products

Carbon Dot-Anchored Cobalt Oxyhydroxide Composite-Based Hydrogel Sensor for On-Site Monitoring of Organophosphorus Pesticides

The development of a portable, quantitative, and user-friendly sensor for on-site monitoring of organophosphorus pesticides (OPs) is significantly urgent to guarantee food safety. Herein, a carbon dot/cobalt oxyhydroxide composite (CD/CoOOH)-based fluorescent hydrogel sensor is constructed for precisely quantifying OPs using a homemade portable auxiliary device. As a fluorescence signal indicator, the orange-emissive CD/CoOOH composite is encapsulated into an agarose hydrogel kit for amplifying the detection signals, shielding background interference, and enhancing stability. Acetylcholinesterase (AChE) catalyzes the hydrolysis of the substrate to produce thiocholine, which induces the decomposition of CoOOH and makes the fluorescence enhancement of the hydrogel platform possible. OPs can specifically block the AChE activity to limit thiocholine production, resulting in a decrease in platform fluorescence. The image color of the fluorescent hydrogel kit is transformed into digital information using a homemade auxiliary device, achieving on-site quantitative detection of paraoxon (model target) with a detection limit of 10 ng mL–1. Harnessing CD/CoOOH composite signatures, hydrogel encapsulation, and portable optical devices, the proposed fluorescence hydrogel platform demonstrated high sensitivity and good anti-interference performance in agricultural sample analysis, indicating considerable potential in the on-site application

Spectra from Investigation on the hydrolytic mechanism of cucurbit[6]uril in alkaline solution

1H-NMR, 13C-NMR and HPL